Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727655 | 1.00 | KDM4E (0.41) | KDM4EOPRL1CYP1A2CYP2D6HIF1A | |
| SCHEMBL2888254 | 0.80 | HCRTR1 (0.44) | KDM4ECYP1A2CYP2D6 | |
| SCHEMBL12734441 | 0.79 | CYP2D6 (0.41) | OPRL1CYP1A2CYP2D6HIF1A | |
| SCHEMBL12734546 | 0.79 | CYP2D6 (0.41) | OPRL1CYP1A2CYP2D6HIF1A | |
| SCHEMBL24359263 | 0.77 | OPRM1 (0.42) | OPRL1CYP1A2CYP2D6HIF1A | |
| SCHEMBL31649403 | 0.77 | OPRL1 (0.41) | KDM4EOPRL1 | |
| SCHEMBL27620525 | 0.76 | HCRTR1 (0.41) | KDM4ECYP2D6 | |
| SCHEMBL27620524 | 0.76 | HCRTR1 (0.41) | KDM4ECYP2D6 | |
| SCHEMBL19934949 | 0.76 | DPP4 (0.46) | KDM4EOPRL1CYP1A2CYP2D6 | |
| SCHEMBL6575510 | 0.76 | CKS1B (0.41) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286201-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286201-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286201-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2190842-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | Glaxo Group Limited (GB) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009034133-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034133-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1289955-B1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2005-04-13 | — | — | EP | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6677354-B2 | TREATING SLEEP, BRAIN, SEXUAL, CARDIOVASCULAR, NERVOUS SYSTEM, PSYCHOLOGICAL, GLANDULAR, AND GASTROINTESTINAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-13 | — | — | US | disclosed |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-02 | — | — | US | disclosed |
| EP-1289955-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096302-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286201-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | HLA-DRB1, HLA-C, BRCA1 | KDM4E 3560/4885OPRL1 607/4885CYP1A2 44/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | KDM4E 1703/4885OPRL1 13/4885CYP1A2 512/4885 |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | HCRTR2, HCRTR1, NPSR1 | KDM4E 1521/4885OPRL1 6/4885CYP1A2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.